Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.
Lumos Diagnostics has received a milestone payment of about US$0.5 million from the U.S. Biomedical Advanced Research and Development Authority, bringing total funding tied to its FebriDx CLIA waiver study to nearly US$3 million and extending its capacity to run further clinical programs, including paediatric studies. The recent CLIA waiver for FebriDx significantly broadens its use to over 300,000 U.S. healthcare sites, enabling access to an estimated 80 million acute respiratory infection patients annually and unlocking a market opportunity of more than US$1 billion, substantially enhancing Lumos’ commercial prospects and competitive position in point-of-care respiratory diagnostics.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics is a medical technology company specializing in rapid, point-of-care diagnostic tests that help healthcare professionals more accurately diagnose and manage medical conditions. The company provides customized assay development and manufacturing services, proprietary digital reader platforms, and develops, manufactures, and commercializes its own Lumos-branded tests targeting infectious and inflammatory diseases.
Average Trading Volume: 4,572,370
Technical Sentiment Signal: Sell
Current Market Cap: A$147.8M
Learn more about LDX stock on TipRanks’ Stock Analysis page.